



Development of injectable fiducial markers for image guided radiotherapy with dual mri and ct visibility

Andresen, Thomas Lars; Jølck, Rasmus Irming; Bruun, Linda Maria

Publication date:
2019

Document Version
Publisher's PDF, also known as Version of record

[Link back to DTU Orbit](#)

Citation (APA):
Andresen, T. L., Jølck, R. I., & Bruun, L. M. (2019). Development of injectable fiducial markers for image guided radiotherapy with dual mri and ct visibility. (Patent No. WO2018215595).

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

(51) International Patent Classification:

A61K 49/00 (2006.01) A61K 49/10 (2006.01)

A61K 49/04 (2006.01) A61K 49/12 (2006.01)

A61K 47/26 (2006.01) A61K 49/14 (2006.01)

A61K 49/08 (2006.01) A61K 49/18 (2006.01)

(21) International Application Number:

PCT/EP2018/063657

(22) International Filing Date:

24 May 2018 (24.05.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1750654-4 24 May 2017 (24.05.2017) SE


(71) Applicants: TECHNICAL UNIVERSITY OF DEN-
MARK [DK/DK]; Anker Engélunds Vej 1, 2800KGS. Lyngby (DK). NANOVI RADIO THERAPY APS
[DK/DK]; Diplomvej 373 N, 2800 KGS. Lyngby (DK).(72) Inventors: ANDRESEN, Thomas; Krogebjerg 68, 2720
Vantose (DK). JØLCK, Rasmus Irming; Buddingevej
25B, 2800 KGS. Lyngby (DK). BRUUN, Linda Maria;
Robert Jacobsens Vej 95, 2 TV, 2300 COPENHAGEN S
(DK).(74) Agent: AWA SWEDEN AB; Box 5117, 200 71 Malmö
(SE).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,(54) Title: DEVELOPMENT OF INJECTABLE FIDUCIAL MARKERS FOR IMAGE GUIDED RADIO THERAPY WITH DUAL
MRI AND CT VISIBILITY

Figure 9. Confocal images and line profiles of formulation 5 (A), 8 (B) and 3 (C) from Table 1. All formulations in Table 1 show clear predominant accumulation at the marker rim, like the examples in this figure.

(57) **Abstract:** Radiation therapy or radiotherapy (RT) is a powerful treatment where precision and accuracy is crucial. Image Guided Radiotherapy (IGRT) facilitates more accurate position verification, correcting for anatomic changes related to internal organ movement. IGRT thereby helps reduce toxicity of radiotherapy and increases relapse-free survival. Currently, the most frequently used imaging-technique for IGRT is Computed Tomography (CT). However, CT- based target delineation of soft tissue tumors tends to only improve the precision and not the accuracy of treatment due to its relatively low soft tissue resolution. In some tumors ~40% larger volumes are defined on CT compared to MRI, a technique with submillimeter soft tissue resolution. Therefore, it is advantageous to apply both CT and MRI in planning of soft tissue tumor radiotherapy. An inter-correlation point with a fixed position and volume (a marker) can be applied to indicate the point of treatment clearly in both imaging modalities and to localize and track tumors in real time. In this study, we present the development of a marker

OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

based on lactose octaacetate:octapropionate 1 : 1 containing 3 mM PLA-DTPA(Gd), 40% triglyceride, 5% propylene carbonate and 10% XSAIB (sucrose based CT-contrast agent). The injectable marker had high CT contrast (>1000 HU) and displayed clearly visible, stable T₁ contrast enhancement (T₁ ~900 ms) in the rim over at least 3 weeks with clinically observable resolution. Key words: Fiducial marker, MRI, CT, Image Guided Radiotherapy

Development of injectable fiducial markers for image guided radiotherapy with dual MRI and CT visibility

Introduction

Radiation therapy or radiotherapy (RT) is an important therapy form used in combination with surgery and chemotherapy for the treatment of cancer [1].

5 Radiotherapy relies on the use of ionizing radiation, and is therefore very dependent on precision and accuracy. Therefore, increasing emphasis is being laid on optimizing radiotherapy volume while facilitating tumor targeted delivery of high radiotherapy doses, resulting in a more efficient treatment with reduced risk of radiation damage to adjacent normal tissues [2]. Image Guided
10 Radiotherapy (IGRT). IGRT facilitates more accurate position verification during the course of fractionated radiotherapy in order to correct for change in tumor position related to internal organ movement caused by respiration, peristalsis and rectal/ bladder filling [3]. Thereby IGRT helps reduce toxicity of radiation treatment while leading to a higher fraction of relapse-free survival [4].

15

The most frequently used imaging-technique for IGRT is Computed Tomography (CT) due to its ability to visualize tumors in both a time- and cost-effective manner. However, CT-based target delineation of soft tissue tumors tends to only improve the precision and not the accuracy of tumor delineation
20 for radiotherapy treatment. An important reason for this is the relatively low soft tissue resolution of this imaging technique [5, 6]. An example of this was seen by *Gao et al* [7], by comparing prostate delineations on CT with anatomical photos, an overestimated target volume of -30% was observed on CT, comparable to the differences in target delineation between CT and MRI. For
25 example, on average, -40% larger prostate volumes are defined on CT compared to MRI, a technique with submillimeter soft tissue resolution [7, 8, 9]. CT-delineations of the prostate also tends to underestimate the dimensions in

the posterior direction, here MRI has a clearly more accurate visualization of prostate anatomy [7, 10, 11]. These observations clearly indicate that it is advantageous to apply both CT and MRI in planning of soft tissue tumor radiotherapy in order to obtain images with sufficient resolution and accurate dimensions. An inter-correlation point with a fixed position and volume (a marker) can be applied to guide treatment planning on both CT and MRI imaging. Such a marker would allow for an easy correlation between the two imaging modalities and a fixpoint to track moving soft tissue tumors on CT in real time during treatment [10].

10

Fiducial markers are used in IGRT in order to track soft tissue tumors in moving tissues where the actual position cannot clearly be correlated to bony anatomy, which is the case for most tumors in abdominal organs and in the lungs [12, 13]. Injectable, fiducial markers based on SAIB (Sucrose Acetate Isobutyrate), ethanol and gold-nanoparticles or a iodine-rich sucrose esters (XSAIB) have been developed in order to improve a technology formerly dominated by solid, difficult to administer markers such as gold seeds [13,14]). The novel SAIB-based fiducial markers are easily administered, non-toxic, biodegradable markers with high CT contrast and high stability over the entire course of radiotherapy [3, 15]. While SAIB-based markers are readily visible in the CT modality due to the high content of heavy atoms (Au or I), the markers result in a hypointense signal in Ti-weighted MRI, often difficult to visualize in tumor tissue [16]. In order to facilitate better visualization in the MRI modality, a Gd chelating moiety can be incorporated in the fiducial marker formulations, resulting in a positive (bright) Ti contrast, easily visualized in the tumor area [17]. Gd-complexes provide high Ti contrast enhancement and are highly stable. They work by shortening of the Ti relaxation of surrounding water molecules.

Gd chelating injectable gels and gel-like formulations are known from literature as a means of achieving high local Ti contrast due to stable, slow tumbling, poly-functionalized complexes often constructed from polymeric materials [18]. The systems described in literature mainly consist of hydrophilic
5 polysaccharides such as chitosan and hyaluronan functionalized with Gd chelators [19, 20] displaying high Ti contrast and retention in tumors lasting several days, however these hydrophilic systems are often not injectable in sufficiently high concentrations, therefore nanoparticle formulations are constructed, and clearance of such particles is relatively fast (within days) from
10 the tumor area, requiring repeated administration. Formulations injectable through thin needles in long endo- or bronchoscopes (EUS/EBUS) and capable of retaining the same size and shape over the typical 6-week period of a fractionated radiotherapy regime, represent the most optimal design. Therefore, the design described in this article is based on injectable, non-
15 viscous formulations of different lactose esters (octaacetate:octapropionate 1:1 or octaisobutyrate) co-formulated with low percentage of solvent and/or short chain triglycerides. The hydrophobicity of the formulations can be tuned to fit the loaded contrast agents as well as therapeutic molecules such as radiosensitizers or other therapeutic molecules loaded in the material to
20 potentiate the effect of radiotherapy. The formulations contain 10 wt% XSAIB (6,6'-di-triiodobenzene-isobutyric-sucrose,) as CT contrast agent and amphiphilic or hydrophilic Gd-chelating molecules (lipids or polymers) as MRI contrast agent. While the hydrophobic CT contrast agent is relatively uniformly distributed throughout the whole formulation, the amphiphilic or hydrophilic Gd-
25 chelating constructs are capable of diffusing to the rim of the material upon injection, providing contrast enhancement at the rim (Figure 1). The presented design provides a clear distinction between CT contrast and MRI contrast in the marker. The work presented in this article provides promising initial results, indicating a clinically applicable concept under development.

Summary of the invention

The present invention is directed to a composition for at least MR imaging, comprising non-water soluble carbohydrates, wherein at least 50% of the non-water soluble carbohydrates are carbohydrates selected from derivatives of lactose, maltose, trehalose, raffinose, glucosamine, galactosamine, lactosamine, sucrose or derivatives of sucrose, or mixed saccharides, or derivatives of disaccharides with at least two pyranose saccharide units, trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 1,000 centipoise (cP) after administration, for use as a medicament, wherein the composition contains at least one imaging contrast agent, and wherein the composition provides a phase separation which provides a clear contrast distinction in MR imaging.

To relate further to prior art, WO201 4/1 87962 discloses an X-ray contrast composition for local administration, wherein the X-ray contrast composition exhibits contrast properties and wherein at least 60% of an administered amount of said X-ray contrast composition remains more than 24 hours within 10 cm from an injection point when the X-ray contrast composition is administered to a human or animal body.

Moreover, in WO201 6/079330 there is disclosed a composition comprising non-water soluble carbohydrates, wherein at least 50% of the non-water soluble carbohydrates are carbohydrates selected from derivatives of lactose, maltose, trehalose, raffinose, glucosamine, galactosamine, lactosamine, or derivatives of disaccharides with at least two pyranose saccharide units, trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 1,000 centipoise (cP) after administration, for use as a medicament.

None of the documents above relate to a composition providing a phase separation such as the composition according to the present invention. The phase separation provided according to the present invention enables the provision of a clear contrast distinction in MR imaging, and especially when MR imaging and CT is combined. This is not hinted or disclosed in WO201 4/1 87962 or WO201 6/079330.

Experimental procedures

Organic synthesis

10 *General experimental conditions:* All reactions were carried out under inert atmosphere (N₂). Water sensitive liquids and solutions were transferred via syringe. Water used for washing of the syntheses was in all cases pure MiliQ water. Organic solutions were concentrated by rotary evaporation at 30-60°C under 200-0 milibar. Thin layer chromatography (TLC) was carried out using
15 aluminium sheets pre-coated with silica 60F (Merck 5554). The TLC plates were inspected under UV light or developed using a cerium ammonium sulphate solution (1% cerium(IV)sulphate and 2.5% hexa-ammonium molybdate in a 10% sulfuric acid solution).

Reagents: DOTA-NHS was purchased from Macrocyclics. All other chemicals
20 were purchased from Sigma Aldrich and were used as received. Dry pyridine was obtained by drying over sieves (4Å) for 2-3 days prior to use.

Instrumentation: Nuclear Magnetic Resonance (NMR) was conducted on a Bruker Ascend™ 400 MHz - operating at 401.3 MHz for ¹H and 100.62 MHz for ¹³C - with a 5 mm H - Broadband Dual Channel z-gradient Prodigy cryoprobe
25 at 298 K, using the residual solvent as internal standard. Recorded chemical shifts were reported in parts per million (δ = scale) downfield from tetramethylsilane, and all coupling constants (J) are expressed in Hz. The FID

files were processed in Mnova Suite version 8.1.4. In ^1H -NMR spectra of α,β anomeric mixtures, the integral of H-1 of the most abundant anomer was always set to 1.0, and the percentage of each anomeric species was calculated from the integral ratio of H-1 α and H-1 β . MALDI-TOF MS was conducted on a Bruker Autoflex SpeedTM instrument. The matrix used for MALDI-TOF was a mixture of 2,5 dihydroxy benzoic acid (DHB), trifluoroacetic acid and Na^+ in ethanol. Preparatory HPLC was conducted on a Waters 600 pump and controller with a Waters 2489 UV/Vis detector.

10 General experimental procedure for synthesis of lactose esters

β -lactose (typically 10-100 g) was suspended in dry pyridine under inert atmosphere (N_2). Hereafter, acetic, propionic or isobutyric anhydride (-2.2 eq per OH) was carefully added, followed by a catalytic amount of DMAP (-0.1 eq).

15 The reactions were heated to $\sim 48^\circ\text{C}$ overnight and then continued for -24 h at r.t. The reactions were then concentrated *in vacuo* and co-evaporated with toluene. The concentrates were dissolved in CHCl_3 and washed with NaHCO_3 (aq) (3x), water (2x), and brine (1x). The organic phases were dried with MgSO_4 (s), filtered, concentrated under reduced pressure and dried *in vacuo*.

20 α,β lactose octaacetate. Yield: 93.7 % yield (mixture of anomers: -30% α and -70 % β). ^1H -NMR: (400 MHz, Chloroform- d) δ 6.24 (d, $J = 3.7$ Hz, 0.4H, H-1 α), 5.66 (d, $J = 8.3$ Hz, 1H, H-1 β), 5.44 (dd, 10.28, 9.53 Hz, 0.4 H), 5.37 - 5.31 (m, 2H), 5.23 (t, $J = 9.1$ Hz, 1H), 5.15 - 5.00 (m, 3H), 4.99 - 4.91 (m, 2H), 4.50 - 4.41 (m, 3H), 4.17 - 4.05 (m, 4H), 3.99 (ddd, $J = 10.2, 4.3, 2.1$ Hz, 0.4H, H5 α), 3.91 - 3.78 (m, 3H), 3.75 (ddd, $J = 9.9, 4.8, 2.0$ Hz, 1H, H5 β), 2.19-1.93 (singlets, -32 H, CH_3 acetyls). MALDI TOF-MS: Calc $[\text{M} + \text{Na}]^+$: 701.59. Found: 701.51. α,β lactose octapropionate. Yield: 84% (mixture of anomers: -30% α and -70 % β). ^1H -NMR (400 MHz, Chloroform- d) δ 6.26 (d, $J = 3.7$ Hz, 0.4H, H-1- α), 5.68 (d, $J = 8.3$ Hz, 1H, H-1 β), 5.47 (dd, 10.3, 9.2 Hz, 0.4 H), 5.38 - 5.33

(m, 2H), 5.26 (t, $J=9.2$ Hz, 1H), 5.15-5.00 (m, 3H), 5.02 - 4.91 (m, 2H), 4.49 - 4.41 (m, 3H), 4.15 - 4.03 (m, 4H), 3.98 (ddd, $J=10.1$, 3.9, 1.8 Hz, 0.4 H, H5 a), 3.91 - 3.77 (m, 3H), 3.73 (ddd, $J=9.9$, 4.6, 2.0 Hz, 1H, H5 β), 2.47 - 2.15 (m, ~23H), 1.19 - 0.99 (m, ~34H). MALDI TOF-MS: Calc $[M+Na]^+$: 813.80.

- 5 Found: 813.42. α,β lactose octaisobutyrate. Yield: 89,5% (mixture of anomers: -30% α and -70% β). 1H NMR (400 MHz, Chloroform- d_3) δ 6.26 (d, $J=3.8$ Hz, 0.4H, H-1 a), 5.68 (d, $J=8.3$ Hz, 1H, H-1 β), 5.48 (dd, $J=10.3$, 9.3 Hz, 0.4 H), 5.40 - 5.34 (m, 2H), 5.27 (t, $J=9.5$ Hz, 1H), 5.18 - 5.00 (m, 3H), 5.03 - 4.91 (m, 2H), 4.50 - 4.41 (m, 3H), 4.24 - 4.02 (m, ~4H), 3.95 (ddd, $J=10.1$, 3.8, 1.7
- 10 Hz, 0.4H, H5 a), 3.91 - 3.80 (m, 3H), 3.70 (ddd, $J=9.9$, 4.5, 2.0 Hz, 1H, H5 β), 2.70 - 2.32 (m, ~11H), 1.26 - 1.01 (m, ~68 H). MALDI TOF-MS: Calc $[M+Na]^+$: 926.02. Found: 925.70.

- PLA-RhB. PLA-NH₂ (Mn ~2500) (260 mg, 0.1 mmol) was suspended in dry DCM (~5 mL). Then, a pre-mixed mixture of Rhodamine-B (105, 0.2 mmol),
- 15 EDC-HCl (80 mg, 0.4 mmol) and DMAP (106 mg, 0.9 mmol) dissolved in 5 mL dry DCM was added, and the reaction was continued at r.t. for ~2 days, where after Kaiser test (negative) indicated completion. The solvents were removed *in vacuo*, and the crude mixture was dissolved in DMSO and purified by dialysis (Mw cutoff: 1000 da) against MQ water for ~14 days. Yield: 299 mg
- 20 (97%). 1H NMR (400 MHz, DMSO- d_6) δ 8.31 (d (br), $J=7.7$ Hz, 1H), 7.95 (br. t, $J=7.4$ Hz, 1H), 7.87 (br. t, $J=7.6$ Hz, 1H), 7.57 - 7.44 (m, 2H), 7.05 - 7.00 (m, 1H), 6.39 - 6.24 (m, ~5H), 5.20 (q, $J=7.1$ Hz, ~33H), 3.65 (dd (br), $J=13.8$, 6.9 Hz, 4H), 3.31 (br. q, $J=7.1$ Hz, 8H), 3.12 - 2.94 (m, 2H), 1.47 (d, $J=7.1$ Hz, ~99H), 1.08 (t, $J=6.9$ Hz, 12H).

- 25 PLA-DTPA. PLA-NH₂ (Mn ~2500) (260 mg, 0.1 mmol) was suspended in dry pyridine (~10 mL) followed by addition of DTPA-dianhydride (57.5 mg, 0.16 mmol) followed by a catalytic amount of DMAP (1.3 mg, 0.01 mmol). The reaction was continued for ~1.5 day, where after Kaiser test (negative) indicated that the reaction was completed. ~5 mL MQ water was added and

stirred for -2 h to hydrolyze the anhydride. The solvents were removed *in vacuo*, and the crude mixture was dissolved in DMSO and purified by dialysis (Mw cutoff: 1000 da) against MQ water for -8-10 days. Yield: 285 mg (96%).

¹H NMR (400 MHz, DMSO-*d*₆) δ PLA-DTPA, DMSO-*D*₆: 8.09 (s, NH, ~1H),
5 5.20 (q, *J* = 7.0 Hz, -33H), 4.21 (dd, *J* = 6.0 Hz, 12.0 Hz, 2H), 4.17 - 4.01 (m, 4H), 3.45 (s, 2H), 3.38 (s, 2H), 3.26 (s, 2H), 3.14 (dd, *J* = 12Hz, 6.0 Hz, 2H), 2.99 (s, 2H), 2.86 (s, 2H), 2.70 - 2.64 (m, 2H), 2.35 - 2.29 (m, 2H), 1.74 (p, *J* = 7.0 Hz, 2H), 1.47 (d, *J* = 7.1 Hz, -99H).

PLA-DOTA. PLA-NH₂ (Mn -2500) (80 mg, 0.032mmol) was suspended in dry
10 dichloromethane (~3 mL), followed by addition of DOTA-NHS (35 mg, 0.0704 mmol) and triethyl amine (40 μL). The reaction was continued for -2.5 days at r.t., where after Kaiser test (negative) indicated completion. The solvent was removed *in vacuo*, and the crude mixture was dissolved in DMSO and purified by dialysis (Mw cutoff: 1000 da) against MQ water for -8-10 days. Yield: 89.6
15 mg (-97%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.23 (s, NH, -1H), 5.21 (q, *J* = 7.0 Hz, -33H), 4.21 (dd, *J* = 13.6, 6.8 Hz, 2H), 4.09 (2 x dd, *J* = 13.6, 6.8, 2H), 3.42 (d of s, 6H), 3.22 - 3.03 (m, -6H), 3.03 - 2.87 (m, -10H), 2.65 (d of s, 2H), 1.79 (p, *J* = 6.9 Hz, 2H). 1.47 (d, *J* = 7.0 Hz, -99H).

DOPE-DOTA. Diacylphosphatidylethanolamine (DOPE) (12 mg, 0.016 mmol)
20 was suspended in dry dichloromethane (~3 mL), followed by addition of DOTA-NHS (18 mg, 0.036 mmol) and triethyl amine (50 μL). The reaction was continued for -2.5 days at r.t., where after kaisertest (negative) and MALDI-TOF of reaction mixture indicated completion. The solvent was removed *in vacuo*, and the crude mixture was dissolved in MeOH:H₂O 40:60 and purified
25 by preparative HPLC (Xterra C8 column, MeCN/H₂O/TFA system. Gradient: 50->100% MeCN in 10 minutes). Yield: 13.5 mg, 74%. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.93 (s, 1H), 5.39 - 5.28 (m, 5H), 5.21 (dddd (br), *J* = 5.6, 3.0 Hz, 1H), 4.21 (dd, *J* = 12.0, 3.1 Hz, 1H), 4.32 (dd, *J* = 12.1, 6.8 Hz, 2H), 4.11 - 4.01 (m, 2H), 3.89 (t, *J* = 6.4 Hz, 2H), 3.49 (dd, *J* = 14.6, 7.3 Hz, 8H) 3.09 (dd,

$J = 14.6, 7.3$ Hz, 15 H), 2.63 (s, 7.5 Hz, 6H), 2.25 (dt, $J = 10.0, 7.5$ Hz, 4H), 1.97 (q, $J = 6.4$ Hz, 8H), 1.40 - 1.13 (m, ~42H), 0.84 (t, 6H). MALDI-TOF MS: Calc $[M+H]^+$: Calc 1131.45, Found: 1131.5.

Formulation

5 The carbohydrate materials as well as the Gd-chelating PLA, PLA-RhB and DOPE-DOTA were used after the synthesis described under the organic synthesis section. DOPE-RhB, DOPE-CF and BSA-DTPA(Gd) were purchased from Avanti Polar Lipids, INC. Absolute EtOH (99%) was purchased from CCS Healthcare. Glycerol trihexanoate (GTH) was purchased from CHEMOS
10 GmbH. PBS was purchased from Fischer Scientific ((Dulbecco's Phosphate buffer saline. Without calcium, magnesium and phenol red). XSAIB (CT-contrast agent) was kindly provided by Nanovi Radiotherapy. All other additives (triglycerides and solvents) were purchased from Sigma Aldrich. All compounds were used as received from the manufacturer.

15 Preparation of formulations containing DOPE-RhB or DOPE-CF

DOPE-RhB was dissolved in EtOH or triglycerides and added to the formulations in amounts resulting in the desired final concentrations ($\sim 1.3 \cdot 10^{-3}$ ug/uL) in formulations consisting of lactose acetate:propionate 1:1/lactose
20 isobutyrate co-formulated with either 25wt% EtOH or 40wt% triglyceride (GTO/GTH), with or without 10wt% EtOH or 5wt% PC (~240 uL formulations in total). The DOPE-RhB solutions were made from a motherstock of 1 mg/mL DOPE-RhB in EtOH with serial dilution into EtOH/triglyceride (GTO/GTH). The injected formulations were imaged in PBS in 8-well microscope slides under
25 the confocal microscope.

DOPE-CF was dissolved in EtOH or triglycerides in concentrations of 1 mg/mL. ~10 uL of this stock was added to ~230 uL carbohydrate formulation to give concentrations of ~ 0,042 ug/uL in formulations consisting of lactose acetate:propionate 1:1/lactose isobutyrate co-formulated with either 25wt% EtOH or 40wt% triglyceride (GTO/GTH), with or without 10wt% EtOH or 5wt% PC. The formulations were imaged in PBS in 8-well microscope slides under the confocal microscope.

Preparation of PLA-RhB formulations

PLA-RhB (Mn~3000) was dissolved in EtOH in concentrations of 5 mg/mL and diluted 100 times into triglyceride (GTH or GTO). ~30 uL of this solutions were added to ~210 uL carbohydrate formulation to give concentrations of ~ 0.0063 ug/uL in formulations consisting of lactose acetate:propionate 1:1/lactose isobutyrate co-formulated with 40wt% triglyceride (GTO/GTH) with or without 10wt% EtOH or 5wt% PC. The formulations were imaged in PBS in 8-well microscope slides under the confocal microscope.

Preparation of formulations containing Gd-chelating molecules

Carbohydrate esters (45 wt%) and XSAIB (10 wt%) were weighed off into a glass vial, followed by addition of tBuOH:water solutions of the Gd-chelator in the wanted concentrations after finished freeze-drying and formulation (3 mM, 1.5 mM, 0.75 mM and 0.3 mM). Aqueous solutions of GdCb were also added to give the same concentrations of both chelator and Gd in the finished materials. The solutions were freeze-dried overnight and subsequently mixed GTH (40 wt%), and PC (5wt%) applying ultrasonication (typically at 40-60°C) and vortexing until homogeneity. The formulations were either used the same day or later after a bit of ultrasonication/vortexing to assure homogeneity.

Confocal Microscopy

Laser Scanning Confocal Microscopy was performed using a Leica TCS SP5 Scanning Laser Confocal Microscope operated using a 61x wet objective and a 561 nm excitation DPPS Laser. Samples (-5-10 uL) were prepared in 8 well
5 microscope slides containing PBS buffer and imaged on the same day to study the distribution of fluorescence signal within the material. In case of Rhodamine B, emission was detected between 575 and 674 nm, while in case of carboxy fluorescein emission was detected between 480 and 580 nm. Multiple images were acquired for each sample and z-stack images were acquired with a 0.5
10 urn spacing between frames. Image processing, including 3D reconstruction and z-stack projections, was performed using FIJI.

In-vitro MRI scans

~100 uL of carbohydrate formulations were scanned in PBS buffer (2 mL glass vials) after formation using a PharmaScan 7T micro MRI scanner. All *in-vitro*
15 MRI scans were conducted with a 3D mouse volume coil (Bruker RF volume coil with 3 cm inner diameter).

T1 RARE imaging

Ti weighted images were obtained by Ti weighted RARE imaging utilizing the following settings: Flip angle: 90°. TR: 1000 ms. TE: 6.8 ms. Echo spacing: 6.8
20 ms, averages: 7, repetitions: 7. Rare factor: 2. Slice thickness: 0.7 mm, slice package of 8 slices was generally applied. FOV: 20 X 20 mm². Image size: 256 X 256 voxels.

In-vivo MRI scans

-50-100 uL of carbohydrate formulations were injected subcutaneously on the
25 hip area of NMRI Nude mice. For intramuscular injection, -25 uL were injected in the thigh area. Pain relief was not necessary, and the injected mice moved around without problems. The mice were MRI scanned at specific timepoints

post injection (same day, 1 day, 1 week, 3 weeks (PLA-formulations only)) using a PharmaScan 7T micro MRI scanner. All *in-vivo* MRI scans were done with a surface coil (Bruker RF surface coil, with a diameter of 2 cm).

T1 RARE imaging

- 5 In-vivo T1 weighted images were obtained by T1 weighted RARE imaging utilizing the following settings: Flip angle: 90°. TR: 1500 ms, TE: 8 ms, Echo spacing: 8 ms, averages: 2, repetitions: 1, Rare factor: 4. FOV: 35 X 35 mm². Image size: 256 X 256 voxels. Slice thickness: 0.7 mm, slice packages of ~9-16 slices, depending on the volume of injected material, were applied.

10 T1 RARE mapping

- T1 values were obtained using saturation recovery experiments performed with a T1 map RARE sequence and 0.7 mm slices (package of 5-16 slices depending on size and shape of injected material). Flip angle: 90°. TR's: 5500, 4000, 3000, 1500, 800, 400 and 200 ms. TE: 7.5 ms averages: 2, repetitions: 1. FOV: 35 x 35 mm², collected into a matrix of 192 x 192 voxels.
- 15 Image data processing and extraction of T1 from maps was performed on ParaVision software version 6.0.1. T1 maps were performed using a nonlinear least square algorithm provided by the Image Sequence Analysis (ISA) tool of ParaVision.

20 Results and discussion

- Formulation of the injectable materials containing fluorophore labeled lipids or polymers were done by mixing the carbohydrate (lactose octaacetate:octapropionate 1:1 or lactose octaisobutyrate), triglyceride (glycerol trihexanoate (GTH) or glycerol trioctanoate (GTO)) containing
- 25 dissolved fluorophore functionalized material and eventual co-solvent (propylene carbonate (PC) or ethanol (EtOH)) followed by ultrasonication until homogeneity. Loading of Gd and Gd chelating polymers or lipids in similar

formulations was done by addition of aqueous solutions of these to the polymer material followed by freeze-drying and the addition of triglyceride and solvent as described above. While the carbohydrate confers structure to the material, the triglyceride ensures the required softness for diffusion and the added co-solvent helps enable diffusion of the added polymer/lipid to the material interface.

In order to easily visualize which molecular structures were capable of diffusing to the rim of the materials after injection and possibly provide T₁ contrast, formulations of fluorophore-functionalized lipids and polymers were examined *in-vitro* by confocal microscopy after injection into PBS. The best performing constructs were then functionalized with Gd-chelating moieties (DOPE/DTPA) and MRI scanned *in-vitro* (in PBS) or *in-vivo* (s.c. or intramuscular injection in mice) using a T₁ RARE sequence. The relaxativity of formulations with the highest contrast was measured by T₁ RARE mapping.

Fluorophore labeled amphiphilic lipids (DOPE derivatives of Carboxy Fluorescein (CF) or Rhodamine B (RhB)) were co-formulated with lactose esters and different additives (See materials and methods). Formulations based lactose octapropionate:octaacetate 1:1 (LAP) or lactose isobutyrate (LI) and EtOH (25 wt%) displayed aggregated lipid particles throughout the matrix, which would result in non-uniform contrast. The formulation based on LAP and GTH (40%) displayed a uniform distribution of aggregated RhB-lipid which would result in a lack of exposure of the majority of the Gd-chelates to water and poor MRI contrast. However slight changes in the LAP: GTH formulation by addition of a co-solvent (5% PC or 10% EtOH) resulted in a clearly higher distribution of DOPE-RhB and DOPE-CF in the rim of the injected formulation (Figure 2), as diffusion to the rim was facilitated by diffusion of solvent. The same result was seen with the LI + 40% GTO-based formulation.

The mixture of the 40% GTO and LI provides a highly hydrophobic environment in which the lipid tails are highly soluble, and the softness of the material makes diffusion to the rim easy.

The formulations seen in Figure 2 were reconstructed with the two Gd-chelating lipids, DOPE-DOTA (Gd) and BSA-DTPA(Gd), as it was hypothesized on the basis of the confocal microscopy experiments, that formulations of similar Gd-chelating constructs would diffuse to the rim of the materials resulting in MRI Ti contrast. Maximum ~3 mM of Gd-chelating lipid could be achieved in the formulations due to solubility limitations. The *in-vitro* (PBS) and *in-vivo* (s.c. injection of mice) results of the formulations are seen in Figure 3 and 4. As seen in Figure 3, BSA-DTPA(Gd) formulations produced a bright rim in both *in-vitro* and *in-vivo*, however DOPE-DOTA(Gd) produced a brighter rim, probably due to DOTA being a more powerful chelator leading to a shorter Ti (-410 ms in the material rim of DOPE-DOTA(Gd) vs ~1188 ms of BSA-DTPA(Gd) in the material rim *in-vivo*, day 1) (See table of Ti relaxation times in supporting information). Both formulations, however, displayed clear leakage of Gd-chelating lipid into the subcutaneous compartment at day 7 (seen by increased bright area in the tissue around the injected material compared to day 1), which lead to decreased soft-tissue resolution. Smaller concentrations of Gd-chelating lipids were therefore tested with DOPE-DOTA(Gd) formulations (Figure 4). All visible concentrations of DOPE-DOTA(Gd) resulted in clear leakage of lipid to the subcutaneous compartment, impairing soft tissue resolution. Hence Gd-lipid based formulations were abandoned as MRI markers. Instead, formulations containing Gd-chelating PLA constructs were investigated to determine their contrast and stability *in-vitro* and *in-vivo*.

Figure 5 shows confocal microscopy images after injection into PBS of PLA-RhB (Mn ~3000 Da) co-formulated with the same components which worked

well for the DOPE-fluorophores: LAP 1:1, 40% GTH + 5% PC and LI, 40% GTO. The LI, 40% GTO formulation performs better in terms of uniform situation of PLA-RhB in the rim of the material, while the LAP, 40% GTH, 5% PC formulation provides less uniform situation of the RhB-polymer in the rim, with more accumulation in the interior of the material. Both formulations display the same tendencies a week after injection, showing a relatively high stability of these formulations. Therefore, PLA-DOTA/DTPA (Gd) formulations were subsequently investigated as MRI contrast agents. MRI *in-vitro* and *in-vivo* results of PLA-DTPA(Gd) and PLA-DOTA(Gd) (~3 mM) formulated in the LAP 1:1, 40% GTH, 5% PC matrix are shown in Figure 6. It was not possible to formulate Gd-chelating polymers or lipids in the LI, 40% GTO matrix due to precipitation in the formulations, therefore only the LAP based formulation was investigated. The PLA-DOTA(Gd) formulation created a broad, more diffuse rim, hard to distinguish from the subcutaneous fat, while the PLA-DTPA(Gd) formulation resulted in a thin, sharp rim easily distinguishable from the subcutaneous fat. The reason for the difference in quality of the MRI images of the two formulations is not clearly known, however the different shape and hydrophilicity of the chelating "head group" could influence diffusion properties of the chelate as well as influence packing of the polymer on the surface of the injected material.

Stability of the PLA-DTPA(Gd) formulation in terms of shape and contrast enhancement, was investigated further both subcutaneously (s.c.) with different concentrations of the chelate, and intramuscularly with the best performing concentration, compared with a blank (Figure 7). The 3 mM PLA-DTPA(Gd) formulation displays a clear white rim both subcutaneously and intramuscularly, retaining contrast relatively well over the full study period of 3 weeks. The lower concentrations were relatively difficult to visualize and clearly distinguish from the subcutaneous fat on MRI, although their rim seemed to

have a slightly higher Ti contrast enhancement than the rim of the blank material (formulated 3 mM PLA without Gd). The high triglyceride content gives the marker a very soft texture, which makes it prone to shape changes over time, especially in moving muscle tissue, where fragmentation of the material was observed probably also associated with the higher pressure and complexity of muscle tissue compared to the s.c. compartment. The fragility of the formulation can be modulated by lowering the triglyceride content, creating a more stable material. Finally, to improve relaxativity, polymers (PLA/PLGA) with multiple Gd-chelation sites can be synthesized and added to the formulation instead of polymers with only one chelation site. This improvement will likely increase Ti relaxation at the rim of the material creating a clearer, more defined contrast between the interior material, the rim and the surrounding tissue.

In-vivo relaxativity of the PLA-DTPA(Gd) formulations imaged in Figure 7 along with Ti contrast level over time of the 3 mM formulation (s.c.) is shown in Figure 8. Due to only one concentration being efficient in enhancing Ti contrast, relaxativity is very small, i.e. $0.159 \pm 0.024 \text{ mM}^{-1}\text{S}^{-1}$. As a comparison, an injectable contrast agent based on Gd-chelating polysaccharide nanogels engineered by *Chan et al* [39], has a relaxativity of $5.4 \text{ mM}^{-1}\text{s}^{-1}$ at 7T, far superior in relaxativity to due to the polyfunctional Gd-chelaton sites and high water content of the material. The hydrophobic material with limited diffusion of polymer to its surface as well as mono-functionalization of PLA with Gd-chelator are the major reasons why the PLA-DTPA(Gd)-formulations from Figure 7 display a low relaxativity. The 3 mM PLA-DTPA(Gd) formulation however displays a fairly short Ti of -877 ms 1 week post injections, a value which only changes slightly throughout the monitoring period. In comparison, the blank material-rim displayed a Ti of ~1400 ms, and the surrounding tissue (s.c. or muscle) had an average Ti of -2600 ms. In order for the contrast

enhancement to be observable in a clinical setting, the product of relaxativity and concentration ($r_1 \cdot [C]$) in the equation $\frac{1}{T_i} = \frac{1}{T_0} + r_1 \cdot [C]$ needs to give at least 10% of the inherent relaxation rate ($1/T_0$) of the blank material and of the surrounding tissue [21]. The 3 mM formulation gives a $r_1 \cdot [C]$ of $\sim 0.5s^{-1}$, i.e.

5 -67% of the inherent T_i relaxation rate of the blank material and $\sim 124\%$ of the inherent relaxation rate of the surrounding tissue, so observable contrast is clinically possible. The bright rims around the injected 3 mM formulations were in average measured to be around ~ 1 mm in diameter, and resolutions up to 0.33 mm^3 can be achieved on clinical 3T MRI scanners, even with short scan

10 times [22]. Hence, the 3 mM PLA-DTPA(Gd) does display promising results in stability of contrast and contrast enhancement even for use in a clinical setup.

Specific embodiments of the present invention

Below some specific embodiments are listed.

15

According to one embodiment of the present invention, the clear contrast distinction is bright vs dark in two different phases of the composition after administration into the human or animal body. This is further seen in the figures.

20

According to yet another embodiment of the present invention the composition is intended for combined MR and CT imaging, and where the composition is arranged to provide a clear distinction between CT contrast and MRI contrast in a marker. As one example, CT may be only be seen in

25 the dark MR area.


Furthermore, according to one embodiment of the present invention, the composition is a liquid before administration into the human or animal body

that increases in viscosity by more than 10,000 centipoise (cP) after administration into the human or animal body. Moreover, the composition may be arranged to be a liquid before administration and with the ability to transform into a gel-like material after administration. Furthermore, the composition may be provided to become a solid material after administration, such as a crystalline or amorphous solid.

Moreover, according to yet another specific embodiment of the present invention, said at least one imaging contrast agent is more concentrated on the surface of the administered material after administration than inside the administered material for at least 1 hour to 3 months after administration, such as for at least 4 hours to 1 month, such as for at least 1 day to 2 months, such as for at least 2 days to 3 months after administration. In another embodiment, said at least one imaging contrast agent is more concentrated less than 1 cm away from the administered material after administration than inside the administered material for at least 1 hour to 3 months after administration, such as for at least 4 hours to 1 month, such as for at least 1 day to 2 months, such as for at least 2 days to 3 months after administration.

Furthermore, according to one embodiment of the present invention, an increase in viscosity after administration into the human or animal body is due to diffusion of a solvent-like molecule out of the administered material and into surrounding tissue.

According to one specific embodiment of the present invention, the non-water soluble carbohydrates are disaccharides with structures selected from:



Formulae: I


II

III

wherein R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , and R_8 in formulae I, II and III are selected collectively from the group consisting of hydrogen, alkanoyl, hydroxyl-substituted alkanoyl, and acyloxy-substituted alkanoyl, alkanyl,

- 5 hydroxysubstituted alkanyl and acyloxy substituted alkanyl; or wherein R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , and R_8 are independently selected from the group consisting of hydrogen, alkanoyl, hydroxyl-substituted alkanoyl, and acyloxy-substituted alkanoyl, alkanyl, hydroxysubstituted alkanyl and acyloxy substituted alkanyl;
- 10 or wherein all groups of R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , and R_8 are selected collectively from the group consisting of acetyl, isobutyryl or propionyl; or wherein R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , and R_8 are independently selected from the group consisting acetyl, isobutyryl or propionyl;
- and wherein both pure anomers and mixtures of α - and β - anomers of the
- 15 above mentioned structural variations are claimed.

According to yet another embodiment, the non-water soluble carbohydrates are trisaccharides with structures selected from:




Formulae IV:

- 20 wherein R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , R_{10} and R_{11} in formulae IV are selected collectively from the group consisting of hydrogen, alkanoyl, hydroxyl-substituted alkanoyl, and acyloxy-substituted alkanoyl, alkanyl, hydroxysubstituted alkanyl and acyloxy substituted alkanyl; or wherein R_1 , R_2 ,

R_3 , R_4 , R_s , R_e , R_7 , R_8 , R_g , R_{10} and R_{11} are independently selected from the group consisting of hydrogen, alkanoyl, hydroxyl-substituted alkanoyl, and acyloxy-substituted alkanoyl, alkanyl, hydroxysubstituted alkanyl and acyloxy substituted alkanyl;

- 5 or wherein all groups of R_i , R_2 , R_3 , R_4 , R_s , R_e , R_7 , R_8 , R_g , R_{10} and R_{11} are selected collectively from the group consisting of acetyl, isobutyryl or propionyl; or wherein R_i , R_2 , R_3 , R_4 , R_s , R_e , R_7 , R_8 , R_g , R_{10} and R_{11} are independently selected from the group consisting acetyl, isobutyryl or propionyl;
- 10 and wherein both pure anomers and mixtures of α - and β - anomers of the above mentioned structural variations are claimed.

- At least 50% of the non-water soluble carbohydrates may be mono- or oligosaccharides containing at least one amino sugar unit. Moreover,
- 15 according to another embodiment, the amino sugar has the structure:



- wherein R_i , R_2 , R_3 , R_4 and R_s in formulae V are selected collectively from the group consisting of hydrogen, alkanoyl, hydroxyl-substituted alkanoyl, and acyloxy-substituted alkanoyl, alkanyl, hydroxysubstituted alkanyl and acyloxy substituted alkanyl; or wherein R_i , R_2 , R_3 , R_4 and R_s are independently selected from the group consisting of hydrogen, alkanoyl, hydroxyl-substituted alkanoyl, and acyloxy-substituted alkanoyl, alkanyl, hydroxysubstituted alkanyl and acyloxy substituted alkanyl, and mono-, di-, tri- or tetra-saccharide derivatives;
- 25 or wherein all groups of R_i , R_2 , R_3 , R_4 and R_s are selected collectively from

the group consisting of acetyl, isobutyryl or propionyl; or wherein R_i , R_2 , R_3 , R_4 and R_5 are independently selected from the group consisting acetyl, isobutyryl or propionyl;

and wherein both pure anomers and mixtures of anomers such as α - and β -
5 anomer centres of the above mentioned structural variations are claimed.

According to one specific embodiment, the non-water soluble carbohydrates comprises poly(ethylene glycol-b-caprolactone) (PEG-PCI), sucrose acetate isobutyrate (SAIB), poly(D,L-lactic acid), or poly(lactic-co-glycolic acid)
10 (PGLA), or a combination thereof. According to another embodiment, the non-water soluble carbohydrates comprise mixed saccharides of furanose and pyranose.

Moreover, according to one specific embodiment of the present invention,
15 said at least one imaging contrast agent makes the composition visible by PET imaging, SPECT imaging, Ultrasound imaging, CT imaging, MR imaging, x-ray imaging, fluoroscopy imaging, fluorescence imaging, or OCT imaging.

Moreover, according to yet another embodiment, the composition contains
20 two imaging contrast agents that are visible by at least two imaging methods, such as visible by at least two imaging methods chosen from PET imaging, SPECT imaging, Ultrasound imaging, CT imaging, MR imaging, x-ray imaging, fluoroscopy imaging, fluorescence imaging, or OCT imaging.

25 Furthermore, according to one embodiment of the present invention the composition contains an imaging contrast agent for CT imaging and an imaging contrast agent for MR imaging.

According to one specific embodiment of the present invention, the composition contains an MR imaging contrast agent containing Gadolinium associated with a chelate. The composition may contain an MR imaging contrast agent containing Gadolinium associated with a chelate that is

5 covalent linked to a polymer. Moreover, the composition may contain an MR imaging contrast agent containing Gadolinium associated with a chelate that is covalent linked to poly lactic acid (PLA). Moreover, the composition may contain an MR imaging contrast agent containing Gadolinium associated with a chelate chosen from PLA-DTPA or PLA-DOTA polymer chelates.

10 Furthermore, the composition may contain a CT contrast agent and an MR imaging contrast agent containing Gadolinium associated with a chelate, and wherein the CT contrast agent is hydrophobic. As mentioned before, the hydrophobic CT contrast agent may be relatively uniformly distributed throughout the whole formulation, and the amphiphilic Gd-chelating

15 constructs are capable of diffusing to the rim.

According to one embodiment, the composition comprises a pharmacologically active compound that is released into the surrounding tissue, such as chemotherapy that enhances the effect of radiotherapy.

20

Furthermore, according to yet another specific embodiment the composition is intended to be administered to the human or animal body through a syringe, an endoscope or a bronchoscope to the target tissue preferably wherein the composition after insertion into the human or animal body constitutes a

25 medical or surgical implant for tissue or surgical adhesion which preferably is wound dressing, a hemostat, enhances tissue regeneration, is a void filler.

The present invention also embodies a medical or surgical implant comprising a composition according to the present invention, wherein the composition is part of a sprayable composition.

5 Moreover, the present invention provides a composition system which may be used as a tissue marker for guided surgery and/or imaging by one or multiple imaging modalities. The composition system may allow for detection of the tissue marker by an external imaging modality if administered or implanted into a mammalian body. Exemplary external imaging modalities include, but
10 are not limited to, X-ray imaging, such as CT imaging, MRI, PET imaging, single photon emission computed tomography (SPECT) imaging, nuclear scintigraphy imaging, ultrasonography imaging, ultrasonic imaging, near-infrared imaging and/or fluorescence imaging.

15 **Examples**

Example 1: Synthesis of carbohydrate esters


General experimental conditions: All reactions were carried out under inert atmosphere (N₂). Water sensitive liquids and solutions were transferred via syringe. Water used for washing of the isolated products was in all cases MilliQ
20 water. Organic solutions were concentrated by rotary evaporation at 30-60°C at 200-0 mbar. Thin layer chromatography (TLC) was carried out using aluminum sheets pre-coated with silica 60F (Merck 5554). The TLC plates were inspected under UV light or developed using a cerium ammonium sulphate solution (1% cerium (IV) sulphate and 2.5% hexa-ammonium molybdate in a
25 10% sulfuric acid solution).

Reagents: DOTA-NHS was purchased from Macrocyclics. All other chemicals were purchased from Sigma Aldrich and were used as received. Dry pyridine was obtained by drying over molecular sieves (4Å) for 2-3 days prior to use.

Instrumentation: Nuclear Magnetic Resonance (NMR) was conducted on a
5 Bruker Ascend™ 400 MHz - operating at 401.3 MHz for ¹H and 100.62 MHz for ¹³C - with a 5 mm H - Broadband Dual Channel z-gradient Prodigy cryoprobe at 298 K using the residual solvent as internal standard. All coupling constants (*J*) are expressed in Hz. The FID files were processed in Mnova Suite. In ¹H-NMR spectra of α,β anomeric mixtures, the integral of H-1 of the most abundant
10 anomer was always set to 1.0, and the percentage of each anomeric species was calculated from the integral ratio of H-1 α and H-1 β. MALDI-TOF MS was conducted on a Bruker Autoflex Speed™ mass spectrometer. The matrix used for MALDI-TOF was a mixture of 2,5 dihydroxy benzoic acid (DHB) spiked with sodium trifluoroacetate in ethanol (60mg/mL).


15 ***General experimental procedure for synthesis of carbohydrate esters***

Lactose (typically 10-100 g) was suspended in dry pyridine under inert atmosphere (N₂). Hereafter, acetic, propionic or isobutyric anhydride (2.2 eq. pr. hydroxyl group) was carefully added. Then, a catalytic amount of DMAP (0.1
20 eq.) was added. The reactions were heated to 48°C overnight, and then continued for 24 hours at room temperature, until TLC and MALDI-TOF showed complete acylation of the starting material. The reactions were concentrated under reduced pressure and co-evaporated with toluene. The concentrates were dissolved in CHCl₃ and washed with NaHCO₃ (aq.) (5x),
25 brine (1x) and water (1x). The organic phases were dried with MgSO₄ (s), filtered, concentrated under reduced pressure and dried *in vacuo*. Yields and reported spectra of individual sugar esters can be found below.

α,β lactose octaacetate

Yield: 93.7 % yield (mixture of anomers: -30% α and -70 % β). **$^1\text{H-NMR}$:** (400 MHz, Chloroform- d) δ 6.24 (d, $J = 3.7$ Hz, 1H, H-1 α), 5.66 (d, $J = 8.3$ Hz, 1H, H-1 β), 5.44 (dd, 10.28, 9.53 Hz, 0.4 H), 5.37 - 5.31 (m, 2H), 5.23 (t, $J = 9.1$ Hz, 1H), 5.15 - 5.00 (m, 3H), 4.99 - 4.91 (m, 2H), 4.50 - 4.41 (m, 3H), 4.17 - 4.05 (m, 4H), 3.99 (ddd, $J = 10.2, 4.3, 2.1$ Hz, 0.4H, H5 α), 3.91 - 3.78 (m, 3H), 3.75 (ddd, $J = 9.9, 4.8, 2.0$ Hz, 1H, H5 β), 2.19-1.93 (singlets, -32 H, CH_3 acetyls). **MALDI TOF-MS:** Calc $[\text{M} + \text{Na}]^+$: 701.59. Found: 701.51.


10

 α,β lactose octapropionate

Yield: 84% (mixture of anomers: -30% α and -70 % β). **$^1\text{H-NMR}$** (400 MHz, Chloroform- d) δ 6.26 (d, $J = 3.7$ Hz, 1H, H-1- α), 5.68 (d, $J = 8.3$ Hz, 1H, H-1 β), 5.47 (dd, 10.3, 9.2 Hz, 0.4 H), 5.38 - 5.33 (m, 2H), 5.26 (t, $J = 9.2$ Hz, 1H), 5.15 - 5.00 (m, 3H), 5.02 - 4.91 (m, 2H), 4.49 - 4.41 (m, 3H), 4.15 - 4.03 (m, 4H), 3.98 (ddd, $J = 10.1, 3.9, 1.8$ Hz, 0.4 H, H5 α), 3.91 - 3.77 (m, 3H), 3.73 (ddd, $J = 9.9, 4.6, 2.0$ Hz, 1H, H5 β), 2.47 - 2.15 (m, -23H), 1.19 - 0.99 (m, -34H). **MALDI TOF-MS:** Calc $[\text{M} + \text{Na}]^+$: 813.80. Found: 813.42.

20


 α,β lactose octaisobutyrate



Yield: 89.5% (mixture of anomers: -30% α and -70 % β). **$^1\text{H NMR}$** (400 MHz, Chloroform- d) δ 6.26 (d, J = 3.8 Hz, 1H, H-1 α), 5.68 (d, J = 8.3 Hz, 1H, H-1 β), 5.48 (dd, J = 10.3, 9.3 Hz, 0.4 H), 5.40 - 5.34 (m, 2H), 5.27 (t, J = 9.5 Hz, 1H), 5.18 - 5.00 (m, 3H), 5.03 - 4.91 (m, 2H), 4.50 - 4.41 (m, 3H), 4.24 - 4.02 (m, ~4H), 3.95 (ddd, J = 10.1, 3.8, 1.7 Hz, 0.4H, H5 α), 3.91 - 3.80 (m, 3H), 3.70 (ddd, J = 9.9, 4.5, 2.0 Hz, 1H, H5 β), 2.70 - 2.32 (m, ~11H), 1.26 - 1.01 (m, ~68 H). **MALDI TOF-MS:** Calc $[\text{M} + \text{Na}]^+$: 926.02. Found: 925.70.

10 Example 2: Synthesis of fluorescently labeled PLA

PLA-RhB




PLA-NH₂ (M_n ~2500) (260 mg, 0.1 mmol) was suspended in dry DCM (~5 mL).
 15 Then, a pre-mixed mixture of Rhodamine-B (105, 0.2 mmol), EDC-HCl (80 mg, 0.4 mmol) and DMAP (106 mg, 0.9 mmol) dissolved in 5 mL dry DCM was

added, and the reaction was continued at r.t. for 2 days, where Kaiser test was negative, indicating full functionalization. The solvents were removed *in vacuo*, and the crude mixture was dissolved in DMSO and purified by dialysis (Mw cutoff: 1000 da) against MQ water for 14 days. **Yield:** 299 mg (97%). **¹H NMR** (400 MHz, DMSO-*d*₆) δ 8.31 (d (br), $J = 7.7$ Hz, 1H), 7.95 (br. t, $J = 7.4$ Hz, 1H), 7.87 (br. t, $J = 7.6$ Hz, 1H), 7.57 - 7.44 (m, 2H), 7.05 - 7.00 (m, 1H), 6.39 - 6.24 (m, ~5H), 5.20 (q, $J = 7.1$ Hz, ~33H), 3.65 (dd (br), $J = 13.8, 6.9$ Hz, 4H), 3.31 (br. q, $J = 7.1$ Hz, 8H), 3.12 - 2.94 (m, 2H), 1.47 (d, $J = 7.1$ Hz, ~99H), 1.08 (t, $J = 6.9$ Hz, 12H).

10

Example 3: Synthesis of Gd-chelators

DOPE-DOTA




15


Diacylphosphatidylethanolamine (DOPE) (12 mg, 0.016 mmol) was suspended in dry dichloromethane (3 mL), followed by addition of DOTA-NHS (1.8 mg, 0.036 mmol) and triethylamine (50 μ L). The reaction was continued for 2.5

days at r.t., where after kaisertest (negative) and MALDI-TOF of the reaction mixture indicated completion. The solvent was removed *in vacuo*, and the crude mixture was dissolved in MeOH:H₂O 40:60 and purified by preparative HPLC (Xterra C8 column, MeCN/H₂O/TFA system. Gradient: 50->100% MeCN in 10 minutes). **Yield:** 13.5 mg, 74%. **¹H NMR** (400 MHz, Chloroform-d) δ 7.93 (s, 1H), 5.39 - 5.28 (m, 5H), 5.21 (dddd (br), J = 5.6, 3.0 Hz, 1H), 4.32 (dd, J = 12.0, 3.1 Hz, 1H), 4.09 (dd, J = 12.1, 6.8 Hz, 1H), 3.95 - 3.78 (m, 4H), 3.49 (dd, J = 14.6, 7.3 Hz, 8H) 3.09 (dd, J = 14.6, 7.3 Hz, ~ 15 H), 2.63 (s, 4H), 2.25 (dt, J = 10.0, 7.5 Hz, 4H), 1.97 (q, J = 6.4 Hz, 8H), 1.40 - 1.13 (m, ~40H), 0.84 (t, 6H). **MALDI-TOF MS:** Calc [M+ H]⁺: Calc 1131.45, Found: 1131.5.

PLA-DTPA



PLA-NH₂ (M_n ~2500) (260 mg, 0.1 mmol) was suspended in dry pyridine (10 mL) followed by addition of DTPA-dianhydride (57.5 mg, 0.16 mmol) and a catalytic amount of DMAP (1.3 mg, 0.01 mmol). The reaction was continued for 1.5 day, where Kaiser test (negative) indicated the reaction was completed. 5 mL MQ water was added and stirred for 2 h to hydrolyze any residual anhydride. The solvents were removed *in vacuo*, and the crude mixture was dissolved in DMSO and purified by dialysis (M_w cutoff: 1000 da) against MQ water for 10 days. **Yield:** 285 mg (96%). **¹H NMR** (400 MHz, DMSO-*d*₆) δ 8.09 (t, J =5.08 Hz, NH, ~1H), 5.20 (q, J = 7.0 Hz, ~33H), 5.47 (s, 1H, OH), 4.21 (q, J = 7.0 Hz, 2H), 4.17 - 4.01 (m, 2H), 3.69 - 3.21 (m, 10H), 3.14 (q, J = 7.0 Hz, ~2H), 3.06 - 2.81 (m, ~6H), 1.74 (p, J = 7.0 Hz, 2H), 1.47 (d, J = 7.0 Hz, ~99H).

PLA-DOTA

PLA-NH₂ (Mn -2500) (80 mg, 0.032mmol) was suspended in dry dichloromethane (3 mL), followed by addition of DOTA-NHS (35 mg, 0.0704 mmol) and triethyl amine (40 μ L). The reaction was continued for 2.5 days at r.t., where Kaiser test (negative) indicated completion. The solvent was removed *in vacuo*, and the crude mixture was dissolved in DMSO and purified by dialysis (Mw cutoff: 1000 da) against MQ water for 8-10 days. **Yield:** 89.6 mg (97%). **¹H NMR** (400 MHz, DMSO-*d*₆) δ 8.23 (s, NH, ~1H), 5.21 (q, *J* = 7.0 Hz, ~33H), 4.21 (q, *J* = 7.0 Hz, 2H), 4.16 - 3.99 (m, 2H), 3.49 - 3.34 (m, 6H), 3.24 - 3.03 (m, 4H), 3.03 - 2.87 (m, ~9H), 2.70 - 2.61 (m, 4H), 1.79 (p, *J* = 7.0 Hz, 2H), 1.63 (d, *J* = 7.1 Hz, 1H), 1.47 (d, *J* = 7.0 Hz, ~99H).

Example 4: In-vitro confocal microscopy of markers containing fluorescent amphiphiles

Laser scanning confocal microscopy was conducted using a Leica TCS SP5 Scanning Laser Confocal Microscope (61x wet objective, 561 nm excitation DPSS Laser) on 5-10 μ L volumes of different marker compositions (see **Table 1**) in PBS buffer in order to investigate distribution of fluorescently labeled amphiphiles in the markers. A predominant distribution to the marker rim indicates the possibility of primary contrast enhancement at the marker rim when formulating the corresponding Gd chelators. The markers were prepared

in 8 well microscope slides containing PBS buffer and imaged the same day. Multiple images were acquired for each sample with a 0.5 μm spacing between z-stack frames. Image processing was performed using FIJI. All formulations listed in **Table 1** show predominant accumulation of fluorophore at the marker-
 5 water interface. Representative results are shown in **Figure 9**.

Table 1. Specifications for preparation of fluorophore containing marker formulations. LAP 1:1 : Lactose octaacetate:octapropionate 1:1. LOIB: Lactose octaisobutyrate. GTH: Glycerol trihexanoate. GTO: Glycerol trioctanoate. PC: Propylene carbonate. EtOH: Ethanol. PLA: Poly-(L-lactide). DOPE: Diacylphosphatidylethanolamine, RhB: Rhodamine B. CF: Carboxy fluorescein.

Formulation#	Composition (w/w%)				Concentration ($\mu\text{g}/\mu\text{L}$)
	Sugar ester	Triglyceride	Solvent		Fluoresc. Amphiphile
1	LAP 1:1	GTH	PC	EtOH	PLA-RhB
	65	40	5	-	0.006
2	LAP 1:1	GTH	PC	EtOH	PLA-RhB
	50	40	-	10	0.006
3	LOIB	GTO	PC	EtOH	PLA-RhB
	60	40	-	-	0.006
4	LAP 1:1	GTH	PC	EtOH	PLA-RhB
	75	20	5	-	0.006
5	LAP 1:1	GTH	PC	EtOH	DOPE-RhB

	65	40	5	-	0.001
6	LAP 1:1	GTH	PC	EtOH	DOPE-RhB
	50	40	-	10	0.001
7	LOIB	GTO	PC	EtOH	DOPE-RhB
	60	40	-	-	0.001
8	LAP 1:1	GTH	PC	EtOH	DOPE-CF
	65	40	5	-	0.04
9	LAP 1:1	GTH	PC	EtOH	DOPE-CF
	50	40	-	10	0.04
10	LOIB	GTO	PC	EtOH	DOPE-CF
	60	40	-	-	0.04

Example 5: *In-vitro* MRI imaging of markers

- 5 Single markers (-50 μ L) containing 3 mM concentrations of different Gd-chelators (see **Table 2**) were injected into 2 mL glass vials containing PBS buffer and investigated using a PharmaScan 7T micro MRI scanner by T1 RARE imaging (Flip angle: 90°. TR: 1000 ms. TE: 6.8 ms. Echo spacing: 6.8 ms, averages: 7, repetitions: 7. Rare factor: 2. Slice thickness: 0.7 mm, slice package of 8. FOV: 20 X 20 mm². Resolution: 256 X 256 voxels) in order to visualize T1 enhancement at the marker-water interface. The markers were MRI scanned while still in the PBS vials within 1 week after injection. All scans were conducted using a 3D mouse volume coil (Bruker RF volume coil with 3 cm inner diameter). Image data processing was performed on ParaVision
- 10

software version 6.0.1 . All markers displayed Ti contrast enhancement at the marker-water interface. The results are shown in **Figure 10**.

Table 2. Specifications for preparation of Gd-containing marker formulations for *in-vitro* MRI scan. LAP 1:1 : Lactose octaacetate:octapropionate 1:1 . GTH: Glycerol trihexanoate. PC: Propylene carbonate. PLA: Poly-(L-lactide). DOPE: Diacylphosphatidylethanolamine, BSA: Bis(stearylamide). DOTA: 1,4,7,10-tetra-azacyclododecane-1,4,7,10-tetraacetic acid. DTPA: diethylenetriaminepentaacetic acid. x-SAIB: 6,6'-di-triiodobenzene-isobuturic-sucrose.

Formulation#	Composition (w/w%)			CT contrast	Concentration (mM)
	Sugar ester	Triglyceride	Solvent		Gd-chelator
1	LAP 1:1	GTH	PC	x-SAIB	BSA-DTPA(Gd)
	45	40	5	10	3
2	LAP 1:1	GTH	PC	x-SAIB	DOPE-DOTA(Gd)
	45	40	5	10	3
3	LAP 1:1	GTH	PC	x-SAIB	PLA-DTPA(Gd)
	45	40	5	10	3
4	LAP 1:1	GTH	PC	x-SAIB	PLA-DOTA(Gd)
	45	40	5	10	3

In-vivo T₁ values

mM PLA-DTPA(Gd)	T1 rim PLA-DTPA(Gd) (msec)	mM DOPE-DOTA(Gd)	T1 rim DOPE-DOTA(Gd) (msec)
3 mM	876.93	3 mM	409.95
1.5 mM	917.79	1.5 mM	779.40
0.75 mM	1089.45	0.75 mM	942.46
0.3 mM	1145.45	0.3 mM	1212.26
No Gd	1421.35	No Gd	1677.27
T1 rim BSA-DTPA(Gd), 3 mM (msec)		T1 rim PLA-DOTA(Gd), 3 mM (msec)	
1188.27		949.28	

Table 3: *In-vivo* T₁ relaxation table of material rims formulated with the above listed species in the stated concentrations. Base formulation was in all cases the LAP 1:1, 40% GTH, 5% PC matrix.

Example 6: *In-vivo* CT and MRI imaging of subcutaneous markers

6.1 : The formulations from **Example 5** were injected in 50 μ L volumes subcutaneously in the hind leg of NMRI Nude mice (n=1 for each formulation). The mice were MRI and CT scanned 1 day and 1 week post injection, utilizing the same scanners, software and coil as in **Example 5**. Both CT scan (Inveon small animal CT scanner (Siemens Medical Systems), processing performed on Inveon software), T₁ RARE imaging (Flip angle: 90°. TR: 1500 ms, TE: 8 ms, Echo spacing: 8 ms, averages: 2, repetitions: 1, Rare factor: 4. FOV: 35 X 35 mm². Resolution: 256 X 256 voxels. Slice thickness: 0.7 mm, slice packages

of -9-16 depending on marker size) and T1 RARE mapping (Flip angle: 90°. TR's: 5500, 4000, 3000, 1500, 800, 400 and 200 ms. TE: 7.5 ms, Echo spacing: 7.5 ms. Rare factor: 2. Averages: 2, repetitions: 1. FOV: 35 × 35 mm², collected into a matrix of 192 × 192 voxels, slice packages of -9-16 depending on marker size) was performed, in order visualize the markers as well as measure the T1 relaxation time at the marker rim. Data processing was performed on ParaVision software version 6.0.1. While the Gd-chelating lipids seemed to leak out of the marker over time, the Gd-chelating PLA analogues did not result in visible leakage but seemed to stay predominantly at the marker-water interface, causing a bright T1 enhancement of the marker rims. The results from day 7 are shown in **Figure 11**.

6.2: The best performing formulation from **Figure 11**, with the clearest contrast enhancement (**Figure 11 a-b**. Formulation 3, **Table 2**), was, injected subcutaneously along with an additional formulation containing 20% triglyceride (see **Table 4**) in the hind leg of NMRI Nude mice (-50 µL volumes, n=4). The mice were then CT and MRI scanned at specific timepoints post injection (MRI: 1 day, 1 week, 2 weeks, 3 weeks, 4 weeks and 6 weeks. CT: week 1, 3 and 6) in order to assess marker volumes, as well as CT and MRI (T1) contrast enhancement over time. The same scan methods, software and equipment as described in **6.1** was employed. All markers displayed T1 enhancement and high CT contrast enhancement over the entire study period. After ended study, the mice were euthanized and the markers removed surgically, no visible irritation or inflammation was present around the markers. The results are shown in **Figure 12.1** and **12.2**.

Table 4. Specifications for preparation of Gd-containing marker formulations for 6-week study *in-vivo* of subcutaneous markers. LAP 1:1: Lactose

octaacetate:octapropionate 1:1. GTH: Glycerol trihexanoate. PC: Propylene carbonate. PLA: Poly-(L-lactide). DTPA: diethylenetriaminepentaacetic acid. x-SAIB: 6,6'-di-triiodobenzene-isobuturic-sucrose.

Formulation#	Composition (w/w%)			Concentration (mM)	
	Sugar ester	Triglyceride	Solvent	CT contrast	Gd-chelator
1	LAP 1:1	GTH	PC	x-SAIB	PLA-DTPA(Gd)
	45	40	5	10	3
2	LAP 1:1	GTH	PC	x-SAIB	PLA-DTPA(Gd)
	65	20	5	10	3

5 Example 7: *In-vivo* CT and MRI imaging of intramuscular marker

Formulation 1 from **Table 4, Example 6.2** (25 μ L) was injected into the thigh muscle of an NMRI Nude mouse to monitor marker stability in frequently moving tissue. The mouse did not show any signs of pain or difficulty moving around, the weight of the mouse also remained stable throughout the experiment. MRI scan was conducted 7 days post injection using the same scanner, T1 RARE scan method and coil as listed in **Example 6.1**. Image processing was performed on ParaVision software version 6.0.1. At 7 days post injection, CT scan of the marker was also performed on the same equipment as listed in **Example 5-6**. The MRI images showed T₁ enhancement at the marker rim. The results are shown in **Figure 13**.

Conclusion

The lactose acetatepropionate 1:1 formulation containing 3 mM PLA-DTPA(Gd), 40% GTH and 5% PC performed well as dual MRI and CT marker over the observation period of 3 weeks. The stable T₁ contrast enhancement displayed sufficient strength and sufficient resolution making it amenable to be observable in patients when using standard clinical MRI facilities and setup. These agents have the potential to result in a novel, commercially applicable, injectable marker for treatment planning and monitoring during IGRT. Future development includes adjusting the triglyceride level and addition of polyfunctional Gd-chelating polymers to achieve both enhanced T₁ contrast as well as a stable 3D structure optimal for tracking *in-vivo*.

Abbreviations

- BSA: Bis(Stearylamine)
- CF: Carboxyfluorescein
- 5 CT: Computed Tomography
- DOPE: Diacylphosphatidylethanolamine
- DOTA: 1,4,7,10-tetra-azacyclododecane-1,4,7,10-tetraacetic acid.
- DTPA: diethylenetriaminepentaacetic acid
- EBUS: Endobronchial Ultrasound
- 10 EDC: 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide.
- EtOH: Ethanol
- EUS: Endoscopic Ultrasound
- G: Gauge ("needle size")
- GTH: Glycerol Trihexanoate
- 15 GTO: Glycerol Trioctanoate
- IGRT: Image Guided Radiotherapy
- LAP: Lactose octaacetate:octapropionate 1:1
- LI: Lactose octaisobutyrate
- MALDI-TOF: Matrix assisted laser desorption/ionization time-of-flight mass
- 20 spectrometry.
- MRI: Magnetic Resonance Imaging
- PBS: Phosphate Buffered Saline
- PC: Propylene Carbonate
- PLA: Polylactic Acid
- 25 RARE: Rapid Acquisition with Relaxation Enhancement

RhB: Rhodamine B

RT: Radio Therapy

SAIB: Sucrose Acetate Isobutyrate

S.C.: Subcutaneous

5 T: Tesla

Ti: Longitudinal relaxation

T2: Transverse relaxation

TE: Echo time

TLC: Thin Layer Chromatography

10 TR: Repetition Time

Wt%: Weight %

XSAIB: 6,6'-di-triidobenzene-isobuturic-sucrose or IodoSAIB

References

- [1]: Radiotherapy Risk Profile WHO/I ER/PSP/2008. 12
- [2]: Baskar, R., Lee, K. A., Yeo, R., & Yeoh, K. W. (2012). Cancer and radiation therapy: current advances and future directions. *Int J Med Sci*, 9(3), 193-199.
- 5 [3]: Goyal, S., & Kataria, T. (2014). Image Guided Radiation Therapy. *J Nucl Med Radiat Ther*, 5(179).
- [4]: Zelefsky, M. J., Kollmeier, M., Cox, B., Fidaleo, A., Sperling, D., Pei, X., Carver, B., Coleman, J., Lovelock, M. & Hunt, M. (2012). Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT
10 for the treatment of clinically localized prostate cancer. *International Journal of Radiation Oncology* Biology* Physics*, 84(1), 125-129.
- [5]: Njeh, C. F. (2008). Tumor delineation: The weakest link in the search for accuracy in radiotherapy. *Journal of Medical Physics*, 33(4), 136.
- [6]: Luna, A., Vilanova, J. C., Da Cruz Jr, L. C. H., & Rossi, S. E. (Eds.).
15 (2013). *Functional Imaging in Oncology: Biophysical Basis and Technical Approaches*. Springer Science & Business Media, 12-13.
- [7]: Gao, Z., Wilkins, D., Eapen, L., Morash, C., Wassef, Y., & Gerig, L. (2007). A study of prostate delineation referenced against a gold standard created from the visible human data. *Radiotherapy and oncology*, 85(2), 239-246.
- 20 [8]: Villeirs, G. M., Van Vaerenbergh, K., Vakaet, L., Bral, S., Claus, F., De Neve, W. J., Verstraete, K.L. & De Meerleer, G. O. (2005). Interobserver Delineation Variation Using CT versus Combined CT+ MRI in Intensity-Modulated Radiotherapy for Prostate Cancer. *Strahlentherapie und Onkologie*, 181(7), 424-430.
- 25 [9]: Bogdanov, A. & Mazzanti, M.L. (2011). Molecular MR Contrast Agents for the Detection of Cancer: Past and Present. *Seminars in oncology* 38.1 42-54.
- [10]: Jonsson, J. H., Garpebring, A., Karlsson, M. G., & Nyholm, T. (2012). Internal Fiducial Markers and Susceptibility Effects in MRI—Simulation and Measurement of Spatial Accuracy. *International Journal of Radiation
30 Oncology* Biology* Physics*, 82(5), 1612-1618.
- [11]: Parker, C. C., Damyanovich, A., Haycocks, T., Haider, M., Bayley, A., & Catton, C. N. (2003). Magnetic resonance imaging in the radiation treatment

planning of localized prostate cancer using intra-prostatic fiducial markers for computed tomography co-registration. *Radiotherapy and oncology*, 66(2), 217-224.

- 5 [12]: Fuller, C. D., & Scarbrough, T. J. (2006). Fiducial markers in image-guided radiotherapy of the prostate. *US Oncological Disease*, 1, 75-9.

[13]: Jolck, R. I., Binderup, T., Hansen, A. E., Scherman, J. B., Munch af Rosenschold, P., Kjaer, A., & Andresen, T. L. (2014). Injectable colloidal gold in a sucrose acetate isobutyrate gelating matrix with potential use in radiation therapy. *Advanced healthcare materials*, 3(10), 1680-1687.

- 10 [14]: Rydhog, J. S., Jolck, R. I., Andresen, T. L., & af Rosenschold, P. M. (2015). Quantification and comparison of visibility and image artifacts of a new liquid fiducial marker in a lung phantom for image-guided radiation therapy. *Medical physics*, 42(6), 2818-2826.

- 15 [15]: Szeto, A., Chin, L., Whelan, P., Wilson, J., & Lee, J. (2014). Image-guided radiation therapy using surgical clips for localization of colonic metastasis from thyroid cancer. *Radiation Oncology*, 9(1), 1.

[16]: <http://nanovi.com/bioxmark/visibility/>, link assessed 24.08.2016

- 20 [17]: Zhou, Z., & Lu, Z. R. (2013). Gadolinium-based contrast agents for magnetic resonance cancer imaging. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*, 5(1), 1-18.

[18]: Kamaly, N., D Miller, A., & D Bell, J. (2010). Chemistry of tumour targeted T1 based MRI contrast agents. *Current topics in medicinal chemistry*, 70(12), 1158-1183.

- 25 [19]: Courant, T., Roullin, V. G., Cadiou, C., Callewaert, M., Andry, M. C., Portefaix, C., Hoeffel, C., de Goldstein, M. C., Port, M., Laurent, S., Elst, L.V., Muller, R., Molinari, M., & Chuburu, F., (2012). Hydrogels incorporating GdDOTA: towards highly efficient dual T1/T2 MRI contrast agents. *Angewandte Chemie International Edition*, 57(36), 9119-9122.

- 30 [20]: Chan, M., Lux, J., Nishimura, T., Akiyoshi, K., & Almutairi, A. (2015). Long-Lasting and Efficient Tumor Imaging Using a High Relaxivity Polysaccharide Nanogel Magnetic Resonance Imaging Contrast Agent. *Biomacromolecules*, 16(9), 2964-2971.

[21]: Dumas, S., Jacques, V., Sun, W. C., Troughton, J. S., Welch, J. T., Chasse, J. M., Schmitt-Willich, H. & Caravan, P. (2010). High relaxivity MRI contrast agents part 1: Impact of single donor atom substitution on relaxivity of serum albumin-bound gadolinium complexes. *Investigative radiology*, 45(10), 560.

[22]: Herrmann, K. H., Schmidt, S., Kretz, A., Haenold, R., Krumbein, I., Metzler, M., Gaser, C., Witte, O.W. & Reichenbach, J. R. (2012). Possibilities and limitations for high resolution small animal MRI on a clinical whole-body 3T scanner. *Magnetic Resonance Materials in Physics, Biology and Medicine*, 25(3), 233-244.

Claims

1. A composition for at least MR imaging, comprising non-water soluble carbohydrates, wherein at least 50% of the non-water soluble carbohydrates are carbohydrates selected from derivatives of lactose, maltose, trehalose,
5 raffinose, glucosamine, galactosamine, lactosamine, sucrose or derivatives of sucrose, or mixed saccharides, or derivatives of disaccharides with at least two pyranose saccharide units, trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 1,000
10 centipoise (cP) after administration, for use as a medicament, wherein the composition contains at least one imaging contrast agent, and wherein the composition provides a phase separation which provides a clear contrast distinction in MR imaging.
- 15 2. The composition according to claim 1, wherein the clear contrast distinction is bright vs dark in two different phases of the composition after administration into the human or animal body.
3. The composition according to claim 1 or 2, wherein the composition is
20 intended for combined MR and CT imaging, and wherein the composition is arranged to provide a clear distinction between CT contrast and MRI contrast in a marker.
4. The composition according to any of the preceding claims, wherein the
25 composition is a liquid before administration into the human or animal body that increases in viscosity by more than 10,000 centipoise (cP) after administration into the human or animal body.

5. The composition according to any of the preceding claims, wherein the composition is a liquid before administration and has the ability to transform into a gel-like material after administration.

5 6. The composition according to any of the preceding claims, wherein the composition becomes a solid material after administration, such as a crystalline or amorphous solid.


7. The composition according to any of the preceding claims, wherein said at
10 least one imaging contrast agent is more concentrated on the surface of the administered material after administration than inside the administered material for at least 1 hour to 3 months after administration, such as for at least 4 hours to 1 month, such as for at least 1 day to 2 months, such as for at least 2 days to 3 months after administration.

15

8. The composition according to any of the preceding claims, wherein said at least one imaging contrast agent is more concentrated less than 1 cm away from the administered material after administration than inside the administered material for at least 1 hour to 3 months after administration,
20 such as for at least 4 hours to 1 month, such as for at least 1 day to 2 months, such as for at least 2 days to 3 months after administration.

9. The composition according to any of the preceding claims, wherein an increase in viscosity after administration into the human or animal body is due
25 to diffusion of a solvent-like molecule out of the administered material and into surrounding tissue.

10. The composition according to any of claims 1-9, wherein the non-water soluble carbohydrates are disaccharides with structures selected from:



5


wherein R₁, R₂, R₃, R₄, R₅, R₆, R₇, and R_s in formulae I, II and III are selected collectively from the group consisting of hydrogen, alkanoyl, hydroxyl-substituted alkanoyl, and acyloxy-substituted alkanoyl, alkanyl, hydroxysubstituted alkanyl and acyloxy substituted alkanyl; or wherein R₁, R₂, R₃, R₄, R₅, R₆, R₇, and R_s are independently selected from the group consisting of hydrogen, alkanoyl, hydroxyl-substituted alkanoyl, and acyloxy-substituted alkanoyl, alkanyl, hydroxysubstituted alkanyl and acyloxy substituted alkanyl;

or wherein all groups of R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , and R_8 are selected
15 collectively from the group consisting of acetyl, isobutyryl or propionyl; or
wherein R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , and R_8 are independently selected from the
group consisting acetyl, isobutyryl or propionyl;

and wherein both pure anomers and mixtures of α - and β - anomers of the above mentioned structural variations are claimed.


20

11. The composition according to any of claims 1-9, wherein the non-water soluble carbohydrates are trisaccharides with structures selected from:



Formulae IV:

- wherein R_i , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , R_{10} and R_{11} in formulae IV are selected collectively from the group consisting of hydrogen, alkanoyl, hydroxyl-substituted alkanoyl, and acyloxy-substituted alkanoyl, alkanyl, hydroxysubstituted alkanyl and acyloxy substituted alkanyl; or wherein R_i , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , R_{10} and R_{11} are independently selected from the group consisting of hydrogen, alkanoyl, hydroxyl-substituted alkanoyl, and acyloxy-substituted alkanoyl, alkanyl, hydroxysubstituted alkanyl and acyloxy substituted alkanyl;
- or wherein all groups of R_i , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , R_{10} and R_{11} are selected collectively from the group consisting of acetyl, isobutyryl or propionyl; or wherein R_i , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , R_{10} and R_{11} are independently selected from the group consisting acetyl, isobutyryl or propionyl;
- and wherein both pure anomers and mixtures of α - and β - anomers of the above mentioned structural variations are claimed.
12. The composition according to any of claims 1-9, wherein at least 50% of the non-water soluble carbohydrates are mono- or oligosaccharides containing at least one amino sugar unit.
13. The composition according to claim 12, wherein the amino sugar has the structure:



- wherein **R_i**, **R₂**, **R₃**, **R₄** and **R_s** in formulae **V** are selected collectively from the group consisting of hydrogen, alkanoyl, hydroxyl-substituted alkanoyl, and acyloxy-substituted alkanoyl, alkanyl, hydroxysubstituted alkanyl and acyloxy substituted alkanyl; or wherein **R_i**, **R₂**, **R₃**, **R₄** and **R_s** are independently selected from the group consisting of hydrogen, alkanoyl, hydroxyl-substituted alkanoyl, and acyloxy-substituted alkanoyl, alkanyl, hydroxysubstituted alkanyl and acyloxy substituted alkanyl, and mono-, di-, tri- or tetra-saccharide derivatives;
- 10 or wherein all groups of **R_i**, **R₂**, **R₃**, **R₄** and **R_s** are selected collectively from the group consisting of acetyl, isobutyryl or propionyl; or wherein **R_i**, **R₂**, **R₃**, **R₄** and **R_s** are independently selected from the group consisting acetyl, isobutyryl or propionyl;
- and wherein both pure anomers and mixtures of anomers such as α- and β-
- 15 anomer centres of the above mentioned structural variations are claimed.
14. The composition according to any of claims 1-9, wherein the non-water soluble carbohydrates comprises poly(ethylene glycol-b-caprolactone) (PEG-PCI), sucrose acetate isobutyrate (SAIB), poly(D,/_-lactic acid), or poly(lactic-
- 20 co-glycolic acid) (PGLA), or a combination thereof.
15. The composition according to any of claims 1-9, wherein the non-water soluble carbohydrates comprise mixed saccharides of furanose and pyranose.

16. The composition according to any of the preceding claims, wherein said at least one imaging contrast agent makes the composition visible by PET imaging, SPECT imaging, Ultrasound imaging, CT imaging, MR imaging, x-ray imaging, fluoroscopy imaging, fluorescence imaging, or OCT imaging.

5

17. The composition according to any of the preceding claims, wherein the composition contains two imaging contrast agents that are visible by at least two imaging methods, such as visible by at least two imaging methods chosen from PET imaging, SPECT imaging, Ultrasound imaging, CT imaging, MR imaging, x-ray imaging, fluoroscopy imaging, fluorescence imaging, or OCT imaging.

10

18. The composition according to any of the preceding claims, wherein the composition contains an imaging contrast agent for CT imaging and an imaging contrast agent for MR imaging.

15

19. The composition according to any of the preceding claims, wherein the composition contains an MR imaging contrast agent containing Gadolinium associated with a chelate.

20

20. The composition according to any of the preceding claims, wherein the composition contains an MR imaging contrast agent containing Gadolinium associated with a chelate that is covalent linked to a polymer.

25

21. The composition according to any of the preceding claims, wherein the composition contains an MR imaging contrast agent containing Gadolinium associated with a chelate that is covalent linked to poly lactic acid (PLA).

22. The composition according to any of the preceding claims, wherein the composition contains an MR imaging contrast agent containing Gadolinium

30

associated with a chelate chosen from PLA-DTPA or PLA-DOTA polymer chelates.

23. The composition according to any of the preceding claims, wherein the
5 composition contains a CT contrast agent and an MR imaging contrast agent containing Gadolinium associated with a chelate, and wherein the CT contrast agent is hydrophobic.

24. The composition according to any of the preceding claims, wherein the
10 composition comprises a pharmacologically active compound that is released into the surrounding tissue, such as chemotherapy that enhances the effect of radiotherapy.

25. The composition according to any of the preceding claims, arranged to
15 be administered to the human or animal body through a syringe, an endoscope or a bronchoscope to the target tissue preferably wherein the composition after insertion into the human or animal body constitutes a medical or surgical implant for tissue or surgical adhesion which preferably is wound dressing, a hemostat, enhances tissue regeneration, is a void filler.

20

26. A medical or surgical implant comprising a composition according to any of the preceding claims, wherein the composition is part of a sprayable composition.







Figure 1. Schematic of the injectable dual CT/MRI fiducial marker after injection into tumor tissue. The material is based on lactose ester (C) and short chain triglycerides (A), CT contrast (B, XSAIB) and amphilipic Gd-chelating molecules (D or E). While the CT contrast agent distributes itself quite evenly within the carbohydrate-triglyceride matrix (indicated by pink) due to its primarily hydrophobic nature, MRI contrast (T_1 contrast) comes from Gd-chelating amphiliphiles (amphiliphilic lipids (D): here DOPE/BSA or polymers (E): here PLA functionalized with a Gd chelator (DOTA or DTPA)) capable of diffusing to the rim of the injected material and affect T_1 of the surrounding water molecules in the tumor, resulting in a bright rim (indicated by purple) around the injected material.

LAP/LI + 40% TG and 5% PC/10%
EtOH, LI + 40% GTO + DOPE-RhB

a)



LAP/LI + 40% TG and 5% PC/10%
EtOH, LI + 40% GTO + DOPE-CF

b)






Figure 2: Confocal microscopy images and line profiles of best performing lactose octaacetate:lactose octapropionate 1:1 (LAP) and Lactose octaisobutyrate (LI) formulations in PBS co-formulated with DOPE-RhB (a) or DOPE-CF (b). As all the best formulations gave largely the same results in terms of line profile and confocal image. A representative formulation (LAP, 40% GTH, 5% PC) is shown in the figure for both lipids.




Figure 3. In-vitro (in PBS) (g-h) and In-vivo (subcutaneous injection) (a-f) imaging (T1 RARE) of formulations consisting of LAP 1:1, 40% GTH and 5% PC with ~3 mM of Gd-chelating lipid. The red arrows show the location of the injected materials on the CT images (e,f).




Figure 4. In-vivo imaging (T1 RARE) of different concentrations of DOPE-DOTA (Gd) imaged at day 1 (a-c), day 2 (d-f) and day 7 (g-i) after injection. Concentrations lower than 0.75 mM did not produce significantly different contrast from the rim of formulations without contrast agent, and are therefore not displayed in the figure (see supporting information for T_1 values of these materials). The 3 mM concentration clearly gave the best T_1 enhancement. All formulations display leakage of Gd-chelating lipid to the subcutaneous compartment (a white streak right under the skin in the area close to the injected materials).




Figure 5: Confocal microscopy images and line profiles of lactose octaacetate:lactose octapropionate 1:1 (LAP) (a) and Lactose octaisobutyrate (LI) (b) formulations co-formulated with PLA-RhB ($M_n \sim 3000$).




Figure 6. In-vitro (in PBS) (e-f) and In-vivo (subcutaneous injection) (a-d) imaging (T1 RARE) of materials formulated with ~3 mM of Gd-chelating PLA polymer (LAP 1:1, 40% GTH and 5% PC formulation). The (red) arrows show the location of the materials on CT scans (c, d).




Figure 7. Further in-vivo studies of the PLA-DTPA(Gd) formulations in different concentrations upon s.c. injection (a-d) compared with the blank (e), the highest concentration 3 weeks after injection (s.c.) (f), and the highest concentration injected in a leg muscle (MRI (g) + CT (h)). The (red) arrows shows the location of the injected material on the CT image (h) and on the MRI image of the blank (e).




Figure 8. In-vivo relaxativity plot of the PLA-DTPA(Gd) formulations imaged in Figure 7 (a) as well as T_1 contrast level in-vivo over time of the 3 mM formulation (b). Due to the pilot-nature of this study (only 1 mouse/ formulation), the measured relaxativity is not an absolute but rather an approximate value, made clear by the standard errors of the slope as well as the intercept shown in the curve equation ($r^2 \sim 0.76$). The T_1 contrast stayed at a relatively stable level throughout the 3-week period.




Figure 9. Confocal images and line profiles of formulation 5 (A), 8 (B) and 3 (C) from **Table 1**. All formulations in **Table 1** show clear predominant accumulation at the marker rim, like the examples in this figure.




Figure 10. T1 RARE imaging of 50 μL markers of formulation 1-4 in designated order. All markers display a bright T₁ contrast enhancement at the rim in PBS buffer.




Figure 11. In-vivo MRI (T1 RARE) and CT imaging of subcutaneous markers formed from formulation 3 (a-b), 4 (c-d), 1 (e-f) and 2 (g-h) in **Table 2**, all imaged 7 days post injection. The lipid Gd-chelators result in T_1 enhancement of the subcutaneous compartment, indicating leakage of lipid-chelators over time. The markers containing PLA-DTPA(Gd) or PLA-DOTA(Gd), do not show clear signs of leakage in the images, and formulation 3 (a-b) shows clear T_1 enhancement still localized to the rim of the marker a week after injection ($T_1 \sim 877$ ms).




Figure 12.1. T_1 contrast enhancement (a), Volume (b) and mean X-ray contrast (c) monitored over time after subcutaneous injection of formulation 1+2, **Table 4** (N=4, Mean \pm SEM). Both formulations display clear CT contrast of the resulting markers as well as T_1 contrast enhancement at the marker rim, a typical example is seen in image image 12.1 c (marker indicated by red arrow). Marker volumes of both formulations remain fairly stable over time.




Figure 12.2. MRI and CT scan images of formulation 1, **Table 4** markers. Both formulation 1 and 2, **Table 4**, result in markers with clear T_1 contrast enhancement at the water-marker interface. The right side of the figure shows a marker (formulation 2, **Table 4**) during and after surgical removal (marker indicated by black arrow). The marker was fully intact and easy to remove, no irritation or inflammation of the surrounding tissue was observed.




Figure 13. MRI imaging (a) and CT imaging (b) of the intramuscular marker 7 days post injection (marker is indicated by red arrows). As seen on image a), there is clear T_1 contrast enhancement at the rim. From both CT and MRI imaging, slight marker fragmentation is seen due to the moving muscle tissue, however the majority of the marker remains localized at the place of injection.

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2018/063657

A. CLASSIFICATION OF SUBJECT MATTER INV. A61K49/00 A61K49/04 A61K47/26 A61K49/08 A61K49/10 A61K49/12 A61K49/14 A61K49/18 ADD.		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal , WPI Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	wo 2016/079330 AI (UNIV DENMARK TECH DTU [DK]) 26 May 2016 (2016-05-26) cited in the applicati on claims 1-26 page 12, line 11 page 17, line 24 - line 27 page 9, line 16 - line 23 page 9, line 31 - page 10, line 7 -----	1-26
<div style="display: flex; justify-content: space-between; align-items: center;"> <div> <input type="checkbox"/> Further documents are listed in the continuation of Box C. </div> <div> <input checked="" type="checkbox"/> See patent family annex. </div> </div>		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search	Date of mailing of the international search report	
13 September 2018	21/09/2018	
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Eberhard, Mi chael	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2018/063657

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
wo 2016079330	AI	26-05-2016	CN 107249570 A	13-10-2017
			EP 3220887 AI	27-09-2017
			JP 2017535556 A	30-11-2017
			WO 2016079330 AI	26-05-2016
